IDEXX Laboratories (IDXX) Expected to Release Quarterly Earnings on Monday

Key Points

• IDEXX Laboratories is expected to report Q3 2026 results before the market opens Monday, November 2. Analysts forecast earnings of $3.72 per share on $1.19 billion in revenue, versus full-year guidance of $14.69–$14.94 EPS.
• The company exceeded expectations in its previous quarter, reporting $4.27 EPS and $1.22 billion in revenue. Revenue increased 9.7% year over year, while analysts project $14.81 EPS for fiscal 2026.
• Wall Street maintains a favorable outlook, with a consensus “Moderate Buy” rating and an average price target of $744.09. Shares recently opened at $560.38, while several analysts have adjusted targets downward but retained overweight or buy ratings.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect IDEXX Laboratories to announce earnings of $3.72 per share and revenue of $1.19 billion for the quarter. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Individuals may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:30 AM ET.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The business had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same period last year, the company earned $3.50 earnings per share. IDEXX Laboratories's quarterly revenue was up 9.7% on a year-over-year basis. On average, analysts expect IDEXX Laboratories to post $14.81 EPS for the current fiscal year and $16.61 EPS for the next fiscal year.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $560.38 on Monday. IDEXX Laboratories has a 1 year low of $500.61 and a 1 year high of $769.98. The firm has a market capitalization of $44.15 billion, a P/E ratio of 39.41 and a beta of 1.55. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The firm's fifty day moving average price is $532.69 and its two-hundred day moving average price is $551.46.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. JPMorgan Chase & Co. decreased their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set an "overweight" rating on the stock in a report on Friday, October 16th. Weiss Ratings upgraded IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. The Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a report on Friday, October 16th. They set a "buy" rating and a $740.00 price target for the company. KeyCorp assumed coverage on IDEXX Laboratories in a research note on Monday, October 12th. They issued a "sector weight" rating on the stock. Finally, Barclays decreased their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 11th. Seven equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus target price of $744.09.

Insider Buying and Selling

In related news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. This trade represents a 18.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.79% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX's companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.